


## Fludarabine triphosphate trisodium

Cat. No.:	HY-136650A
Molecular Formula:	C <sub>10</sub> H <sub>12</sub> FN <sub>5</sub> Na <sub>3</sub> O <sub>13</sub> P <sub>3</sub>
Molecular Weight:	591.12
Target:	Drug Metabolite; Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Apoptosis
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 125 mg/mL (211.46 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.6917 mL	8.4585 mL	16.9170 mL	
5 mM	0.3383 mL	1.6917 mL	3.3834 mL	
10 mM	0.1692 mL	0.8459 mL	1.6917 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of [Fludarabine](#) (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC<sub>50</sub> of 2.3 μM and a K<sub>i</sub> of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 2.3 ± 0.3 μM (DNA primase); Ki: 6.1 ± 0.3 μM (DNA primase)<sup>[1]</sup>

#### In Vitro

Fludarabine triphosphate trisodium is a more potent inhibitor of the polydeoxythymidylate primase activity than of the DNA polymerase α/δ activities present in the supernatants of CCRF-CEM cells<sup>[1]</sup>.

Fludarabine triphosphate trisodium (10-50 μM) inhibits the incorporation of ATP into primer RNA and dTTP into DNA to a similar extent<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Catapano CV, et al. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. *Cancer Res.* 1991 Apr 1;51(7):1829-35.

[2]. Woodahl EL, et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. *Cancer Chemother Pharmacol.* 2009 Feb;63(3):391-401.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA